HUMALOG (insulin lispro) by Eli Lilly and Company. Approved for insulin analog [epc]. First approved in 1996.
Drug data last refreshed 18h ago · AI intelligence enriched 3w ago
Humalog (insulin lispro) is a rapid-acting insulin analog manufactured by Eli Lilly and Company, approved in 1996. It is indicated for the treatment of diabetes mellitus by lowering blood glucose through stimulation of peripheral glucose uptake and inhibition of hepatic glucose production. The drug works by binding to insulin receptors and also inhibits lipolysis and proteolysis while enhancing protein synthesis. As a rapid-acting insulin, Humalog is typically used for mealtime coverage in insulin regimens and represents a foundational product in modern diabetes care.
Insulin Analog
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Study to Demonstrate Pharmacokinetic and Pharmacodynamic Similarity Between NKF-INS(L), US-Humalog®, and EU-Humalog®
Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin Degludec
A Trial Comparing the Pharmacodynamics and Pharmacokinetics of BC Combo THDB0207 and Lantus® and Humalog® in Subjects With Type 1 Diabetes
A Trial Investigating the Pharmacodynamics of BC Combo THDB0207 Compared With Humalog® Mix25 and Simultaneous Injections of Humalog® and Lantus® in Healthy Chinese Volunteers
A Study of LY900014 (Lyumjev) Versus Insulin Lispro (Humalog) in Participants With Type 1 Diabetes
Worked on HUMALOG at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo$458M Medicare spend — this is a commercially significant brand
Humalog's approaching loss of exclusivity creates opportunities in competitive intelligence, health economics, and patient access roles as Eli Lilly prepares for biosimilar competition. Sales and medical science liaison roles remain active for defending market share against Novo Nordisk and Sanofi competitors, though headcount may shift toward specialty diabetes management and outcomes-based contracting. Currently, zero open roles are linked to this product in available career databases, but positions in insulin market defense, payer relations, and patient assistance programs are likely emerging.